DOI: 10.1212/01.CON.0000527785.38930.b9
,
Issn Print: 1080-2371
Publication Date: 2017/12/01
Facebook
Twitter
LinkedIn
Email
 |
Checking for direct PDF access through Ovid | |
Excerpt
Professor of Neurology; Vice Chair for Education, University of Pennsylvania, Philadelphia, Pennsylvania
aDr Pruitt receives research/grant support as principal investigator of a Copaxone study from TEVA Pharmaceuticals.
bDr Pruitt discusses the unlabeled/investigational use of B-Raf proto-oncogene serine/threonine kinase inhibiters, cytotoxic T-lymphocyte–associated antigen 4 inhibitors, and programmed death receptor 1 inhibitors for the treatment of melanoma and non–small cell lung cancer metastases.
Tracy T. Batchelor, MD, MPH
Count Giovanni Auletta Armenise Professor of Neurology, Harvard Medical School; Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Co-leader, Neuro-Oncology Program, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts
aDr Batchelor serves on the scientific advisory boards of Acerta Pharma; Amgen Inc; Cavion; F. Hoffmann-La Roche Ltd; Mateon Therapeutics, Inc; Merck & Co, Inc; NXDL; and Proximagen Limited. Dr Batchelor serves on the editorial boards of Cancer and Neuro-Oncology and receives publishing royalties from UpToDate, Inc. Dr. Batchelor receives research grant support from the National Institutes of Health (2 K12 CA 090554-16, 1 P50 CA 165962-04, 2 ROI CA 129371-09, 2 K24 CA 125440-10, 2 R13 CA 124293-10).
bDr Batchelor discusses the unlabeled/investigational use of buparlisib, ibrutinib, lenalidomide, methotrexate, pembrolizumab, pemetrexed, pomalidomide, temozolomide, and temsirolimus for the treatment of primary central nervous system lymphoma.
Jaishri O. Blakeley, MD
Associate Professor of Neurology, Neurosurgery, and Oncology; Director, Comprehensive Neurofibromatosis Center, Neurofibromatosis Therapeutic Acceleration Program, Johns Hopkins University Brain Cancer Program, Johns Hopkins University, Baltimore, Maryland
aDr Blakeley serves as a consultant for AbbVie Inc and receives research/grant support from the Children’s Tumor Foundation, Eli Lilly and Company, GlaxoSmithKline plc, the National Cancer Institute (U54 CA196519), the National Institute of Neurological Disorders and Stroke (R13 NS08461903), and Sanofi Genzyme.
bDr Blakeley discusses the unlabeled/investigational use of intracavitary bleomycin for craniopharyngioma; AZD2014, bevacizumab, GSK2256098, hydroxyurea, octreotide, SMO-targeting agents, and sunitinib for meningioma; bromocriptine for pituitary tumors; and bevacizumab and everolimus for vestibular schwannoma.
Mai Dang, MD, PhD
Attending Physician, Children’s Hospital of Philadelphia; Instructor, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
aDr Dang receives research/grant support from the Gray Matters Foundation; the Musella Foundation for Brain Tumor Research & Information, Inc; and the National Institutes of Health.
bDr Dang reports no disclosure.
Jorg Dietrich, MD, PhD
Clinical Director, Massachusetts General Hospital; Assistant Professor, Harvard Medical School, Boston, Massachusetts
aDr Dietrich serves on the editorial board of Neuro-Oncology Practice and has received personal compensation as a consultant for Monteris Medical, Inc. Dr Dietrich receives publishing royalties from UpToDate, Inc and research/grant support from the National Institutes of Health.
bDr Dietrich reports no disclosure.
Catherine H. Han, MD
Medical Oncologist, Auckland Cancer Society Research Centre, School of Medical Sciences, Auckland, New Zealand; Faculty, Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Visiting Medical Oncologist, Departments of Neurology and Radiation Oncology, Division of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts
aDr Han reports no disclosure.
bDr Han discusses the unlabeled/investigational use of buparlisib, ibrutinib, lenalidomide, methotrexate, pembrolizumab, pemetrexed, pomalidomide, temozolomide, and temsirolimus for the treatment of primary central nervous system lymphoma.
Jason T. Huse, MD, PhD
Associate Professor, Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas
aDr Huse has received personal compensation as a consultant for Champions Oncology, Inc and receives research/grant support from the American Cancer Society (RSG-16-170-01-DMC) and the National Cancer Institute/National Institutes of Health (P50CA127001, GC227828).
bDr Huse reports no disclosure.
Joshua P.
